Amgen (AMGN) Earnings Date & Reports

Key Takeaways

• Amgen is expected to report Q2 2026 results around July 30–August 4, 2026, with consensus revenue estimates near $9.41 billion and non-GAAP earnings per share (EPS) of approximately $5.59.
• Year-over-year EPS is projected to decline roughly 7%, reflecting a challenging comparison against the exceptionally strong $6.02 reported in Q2 2025.
• Analyst sentiment remains cautious but not bearish, with the consensus rating at Hold and an average 12-month price target near $356, below recent trading levels around $363–$374.
• Key growth products including Repatha and Evenity are drawing attention, while legacy osteoporosis drugs Prolia and Xgeva face accelerating biosimilar erosion.
• Amgen has beaten consensus EPS estimates for at least four consecutive quarters, though the magnitude of positive surprises has been narrowing.
• Full-year 2026 guidance calls for revenue of $37.1–$38.5 billion and non-GAAP EPS of $21.70–$23.10, providing a framework against which Q2 performance will be measured.

Earnings Context and Why It Matters

Amgen's Q2 2026 report arrives at a pivotal moment for the biotech giant. The company is navigating a transitional period in which its portfolio of newer growth drivers—including Repatha, Evenity, Uplizna, and TEPEZZA—must increasingly offset revenue declines from legacy blockbusters facing biosimilar competition. Prolia and Xgeva, two long-standing osteoporosis franchises, are expected to see accelerating sales erosion as additional biosimilar entrants reach the market. Meanwhile, the pipeline narrative around MariTide and olpasiran continues to build, and investors are looking for any updates that could reshape the long-term growth story. With Amgen shares trading near the upper end of their 52-week range and above the average analyst price target, the market's reaction to this report could set the tone for the stock through the remainder of 2026.

Earnings Expectations

Wall Street analysts expect Amgen to deliver Q2 2026 revenue of approximately $9.41 billion, based on Yahoo Finance consensus data from 24 analysts, with estimates ranging from $9.10 billion to $9.63 billion. This would represent roughly 2.5% year-over-year growth from the $9.18 billion reported in Q2 2025. On the bottom line, consensus non-GAAP EPS stands at $5.59, implying a decline of about 7% from the $6.02 earned in the same quarter last year—a quarter that included unusually strong results and a 14% upside surprise.

Guggenheim, which maintains a Neutral rating, recently trimmed its Q2 2026 estimates to $9.39 billion in revenue and $5.46 in EPS, citing weaker-than-expected prescription trends for Krystexxa and Otezla. Bank of America projects $9.38 billion in revenue with EPS of $5.58. Amgen's own full-year guidance, reaffirmed during the Q1 2026 call in April, calls for non-GAAP operating margins in the 45–46% range for product sales, with Q2 margins expected to remain roughly in line with Q1 levels. Investors will be closely monitoring product-level sales trends, particularly the performance of the company's six designated growth drivers, which delivered 24% aggregate growth in Q1 2026 and represented roughly 70% of total product sales.

AI Screener

For investors seeking to identify opportunities ahead of major earnings events like Amgen's Q2 report, Tickeron's AI Screener offers a powerful AI-driven solution. The AI Screener enables traders and investors to filter thousands of stocks and ETFs using customizable criteria including technical patterns, fundamental metrics, volatility profiles, and proprietary AI-generated signals. Users can scan by industry, market capitalization, specific technical indicators, price pattern formations, and performance benchmarks to surface trade ideas, breakout candidates, and emerging trends far more efficiently than manual screening methods allow. Whether tracking biotech earnings season or monitoring broader sector rotations, the AI Screener helps transform raw market data into actionable insights.

Market Reaction and Investor Sentiment

Heading into the Q2 2026 report, investor sentiment around Amgen appears balanced but leaning cautious. The stock has rallied meaningfully from its 52-week low of $269.77 and recently traded near $371, placing it above the average analyst price target of approximately $356. This premium valuation relative to consensus targets suggests that some optimism is already priced in, which raises the bar for a positive post-earnings reaction. Amgen's recent history of earnings beats is well-established—the company has topped consensus EPS estimates for at least four straight quarters—but the magnitude of those beats has been shrinking, from a 14.5% surprise in Q2 2025 to an 8% surprise in Q1 2026. Additionally, Q1 2026 results, despite beating estimates, were followed by a nearly 5% sell-off, indicating that the market may be demanding more than just modest beats to sustain upward momentum. Key risk factors include the pace of biosimilar erosion on Prolia and Xgeva, any downward adjustment to full-year guidance, and the potential for pipeline setbacks.

Forward Outlook and Key Factors to Monitor

Beyond the headline Q2 numbers, several forward-looking dynamics will shape Amgen's investment narrative through the second half of 2026.

First, the trajectory of the company's growth portfolio is critical. Repatha and Evenity have shown stronger-than-expected prescription volumes according to recent IQVIA data, and continued momentum here could help offset softness in other areas. Conversely, Krystexxa and Otezla script trends have underwhelmed, and any further deterioration could pressure the top line. The six-product growth-driver aggregate—which also includes Uplizna, TEPEZZA, and Imdeltra—remains the central metric for assessing Amgen's transition away from legacy dependence.

Second, biosimilar erosion on Prolia and Xgeva is expected to accelerate through the year as more competitors enter. Guggenheim and other firms have already reduced long-term estimates for these products. Investors should watch for any commentary from management about the pace of volume and price declines relative to internal forecasts.

Finally, pipeline catalysts remain an important undercurrent. MariTide and olpasiran represent significant longer-term opportunities in cardiometabolic disease, and any clinical or regulatory updates—whether positive or negative—could materially influence the stock. Amgen's continued investment in AI-driven research and development (R&D) productivity, highlighted during the Q1 call, also signals the company's intent to maintain a competitive edge in discovery efficiency.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations